RHYTHM PHARMACEUTICALS, INC.
No SEC Form 4 filings for $RYTM in the last 30 days.
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported preliminary Phase 2 results for RM-718, a once-weekly MC4R agonist, in acquired hypothalamic obesity. In 7 patients completing 16 weeks, mean BMI fell 11.6% from baseline. The company cited comparisons versus bivamelagon (10.1% at 14 weeks) and setmelanotide (10.1% at 16 weeks). Mild injection-site hyperpigmentation and common GI side effects were reported.
Rhythm Pharmaceuticals (RYTM) shares rose 2.9% to $105.78 after a Q2 update. Global net product sales increased to $71.3 million, including early IMCIVREE demand, while the company reported a net loss of $50.4 million. Revenue rose year over year from $48.5 million, but losses widened slightly.
Rhythm Pharmaceuticals (RYTM) reported preliminary Phase 2 results for RM-718, an investigational once-weekly MC4R agonist for acquired hypothalamic obesity. In 11 enrolled patients, 7 reached 16 weeks. Interim data showed mean BMI down 11.6% from baseline, with two mild injection-site hyperpigmentation cases and generally tolerable side effects. Two discontinued; eight remained on treatment as of mid-July 2026.
Over the past 7 days, alphai's AI scored 7 news stories mentioning RYTM (RHYTHM PHARMACEUTICALS, INC.). Coverage has skewed bullish: 5 bullish, 1 neutral, and 1 bearish.
Recent RYTM coverage spans technology, earnings and financial news.
Early Phase 2 efficacy and tolerability signals for RM-718 could shift expectations for obesity pipeline value, but the small n and preliminary nature limit conviction.
Near-term sentiment is supported by strong HO product sales growth, but the widening loss and cash runway risk likely cap upside until operating leverage improves.
Positive interim Phase 2 efficacy and tolerability for RM-718 should support bullish sentiment, but the small sample size and preliminary nature limit conviction.
Near-term trading focus is on RM-718 efficacy/tolerability read-through plus updated cost guidance and expanding IMCIVREE reimbursement and launch plans in Japan and Europe.
Guidance reduction tied to higher commercialization spend and expense outlook likely pressures near-term sentiment, despite >50% IMCIVREE revenue growth.
alphai scores every news story that mentions RYTM with an AI model for sentiment and relevance, and aggregates insider trades from RHYTHM PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported preliminary Phase 2 results for RM-718, a once-weekly MC4R agonist, in acquired hypothalamic obesity. In 7 patients completing 16 weeks, mean BMI fell 11.6% from baseline. The company cited comparisons versus bivamelagon (10.1% at 14 weeks) and setmelanotide (10.1% at 16 weeks). Mild injection-site hyperpigmentation and common GI side effects were reported.
4 min readRhythm Pharmaceuticals (RYTM) shares rose 2.9% to $105.78 after a Q2 update. Global net product sales increased to $71.3 million, including early IMCIVREE demand, while the company reported a net loss of $50.4 million. Revenue rose year over year from $48.5 million, but losses widened slightly.
6 min readRhythm Pharmaceuticals (RYTM) reported preliminary Phase 2 results for RM-718, an investigational once-weekly MC4R agonist for acquired hypothalamic obesity. In 11 enrolled patients, 7 reached 16 weeks. Interim data showed mean BMI down 11.6% from baseline, with two mild injection-site hyperpigmentation cases and generally tolerable side effects. Two discontinued; eight remained on treatment as of mid-July 2026.
4 min readRhythm Pharmaceuticals (NASDAQ:RYTM) reported Q2 U.S. product revenue of $51M (72% of product sales) and said growth was driven by acquired HO and Bardet-Biedl syndrome demand. International revenue fell to $20.3M due to a France Contribution M charge. GAAP net loss was $0.73/share; cash was ~$331M. RM-718 Phase II Part C showed 11.6% mean BMI reduction at week 16 in 7 patients.
7 min readRhythm Pharmaceuticals (RYTM) reported a wider Q2 2026 net loss of $50.36M, or $0.73/share, versus $47.98M, or $0.75/share, as higher operating expenses outweighed 50%+ revenue growth to $71.25M driven by IMCIVREE sales. The company cut FY26 non-GAAP operating expense guidance to $363M-$397M and provided RM-718 and IMCIVREE clinical updates.
4 min readRHYTHM PHARMACEUTICALS, INC. (RYTM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningspr_draft.htm EX-99.1 Document EXHIBIT 99.1 Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update -- U.S. launch of IMCIVREE ® (setmelanotide) for acquired hypothalamic obesity (HO) starts strong with more than 400 patient
6 min readRhythm Pharmaceuticals (Nasdaq: RYTM) reported preliminary Phase 2 open-label data for RM-718, a once-weekly MC4R agonist, in acquired hypothalamic obesity. Eleven patients were enrolled; among 7 assessed at Week 16, mean BMI fell 11.6% from baseline. The company cited similar BMI declines to bivamelagon and setmelanotide and reported limited mild injection-site hyperpigmentation. Two patients discontinued due to adverse events.
5 min readA phase 3 trial in NEJM found setmelanotide (1.5 to 3.0 mg daily) reduced BMI more than placebo over 52 weeks in patients aged 4 to 66 with acquired hypothalamic obesity. BMI change was -16.5% vs 3.3%. Hunger scores fell more with setmelanotide. Adverse events occurred in 100% vs 90%. Rhythm Pharmaceuticals is the manufacturer.
4 min readA roundup of Monday analyst actions across many stocks. Piper Sandler upgraded Rivian (RIVN) and Mobileye (MBLY) to overweight, and initiated Williams-Sonoma (WSM) overweight with a $253 target. Other calls include Alphabet (GOOGL) buy, Cameco (CCJ) buy, Nvidia (NVDA) outperform, Apple (AAPL) buy with $370 target, and Tesla (TSLA) buy with $420 target.
2 min readThe article previews Monday’s Wall Street analyst calls and a busy earnings week, citing over 150 S&P 500 companies scheduled to report. It lists upgrades, downgrades, and initiations for specific stocks, including Alphabet (GOOGL) Buy to $425, Ford (F) Buy to $17.50, Stellantis (STLA) double downgrade to $4, and Clean Harbors (CLH) Buy to $360. It also notes Bitcoin at $65,149 and gold at $4,051.
6 min read
